Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION(2023)

引用 0|浏览2
暂无评分
摘要
This study evaluates whether FDA-approved novel cancer therapeutics supported by pivotal trials with adequate representation of minoritized groups were associated with slower clinical development times than those with inadequate representation.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要